| BID | 0.9100 | ASK | 0.9500 | ||
| Open | 0.9301 | Previous Close | 0.9301 | ||
| Pre-Market | 0.99 | After-Market | - | ||
| 0.06 6.43% | - - |
| Target Price | 7.30 | Analyst Rating | Hold 3.00 | |
| Potential % | 702.20 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★ 47.25 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★+ 47.24 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 1.32 | Earnings Rating | — | |
| Market Cap | 93.41M | Earnings Date | 21st Nov 2023 | |
| Alpha | -0.06 | Standard Deviation | 0.21 | |
| Beta | 0.27 |
Today's Price Range 0.91000.9898 | 52W Range 0.87133.80 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.89% | ||
| 1 Month | -32.11% | ||
| 3 Months | -55.07% | ||
| 6 Months | -66.90% | ||
| 1 Year | -64.77% | ||
| 3 Years | -96.17% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -49.54 | |||
ROE last 12 Months | -56.30 | |||
ROA (5Y Avg) | -13.24 | |||
ROA last 12 Months | -45.63 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -57.56 | |||
Return on invested Capital Q | -16.30 | |||
Return on invested Capital Y | -36.28 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 2.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.30 | ||||
| 1.67 | ||||
| 3.96 | ||||
| - | ||||
| -3.30 | ||||
| -0.70 | ||||
| 1.10 | ||||
| 1.78 | ||||
| 145.58M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.20 | ||||
| 3.70 | ||||
| 0.02 | ||||
| 0.05 | ||||
| -32 696.20 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 67.60 | ||||
| -178.60 | ||||
| -178.60 | ||||
| -115.30 | ||||
| -97.54 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 59.16M | ||||
| 0.67 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | - | -0.18 | - |
| Q01 2023 | -0.20 | -0.26 | -30.00 |
| Q04 2022 | - | -0.31 | - |
| Q03 2022 | -0.28 | -0.31 | -10.71 |
| Q02 2022 | -0.36 | -0.37 | -2.78 |
| Q01 2022 | -0.23 | -0.39 | -69.57 |
| Q04 2021 | - | -0.38 | - |
| Q03 2021 | -0.19 | -0.25 | -31.58 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 21st Nov 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 8.54K |
| Shares Outstanding | 102.64K |
| Shares Float | 48.04M |
| Trades Count | 111 |
| Dollar Volume | 8.11K |
| Avg. Volume | 55.37K |
| Avg. Weekly Volume | 18.15K |
| Avg. Monthly Volume | 83.71K |
| Avg. Quarterly Volume | 64.23K |
Burning Rock Biotech Limited (NASDAQ: BNR) stock closed at 0.9301 per share at the end of the most recent trading day (a -5.09% change compared to the prior day closing price) with a volume of 10.03K shares and market capitalization of 93.41M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 753 people. Burning Rock Biotech Limited CEO is Yusheng Han.
The one-year performance of Burning Rock Biotech Limited stock is -64.77%, while year-to-date (YTD) performance is -58.66%. BNR stock has a five-year performance of %. Its 52-week range is between 0.871349 and 3.8, which gives BNR stock a 52-week price range ratio of 1.32%
Burning Rock Biotech Limited currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 1.67, a price-to-sale (PS) ratio of 3.96, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -45.63%, a ROC of -57.56% and a ROE of -56.30%. The company’s profit margin is -97.54%, its EBITDA margin is -178.60%, and its revenue ttm is $59.16 Million , which makes it $0.67 revenue per share.
Of the last four earnings reports from Burning Rock Biotech Limited, there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Burning Rock Biotech Limited’s next earnings report date is 21st Nov 2023.
The consensus rating of Wall Street analysts for Burning Rock Biotech Limited is Hold (3), with a target price of $7.3, which is +702.20% compared to the current price. The earnings rating for Burning Rock Biotech Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Burning Rock Biotech Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Burning Rock Biotech Limited has a Sell technical analysis rating based on Technical Indicators (ADX : 21.65, ATR14 : 0.10, CCI20 : -62.75, Chaikin Money Flow : -0.05, MACD : -0.12, Money Flow Index : 43.46, ROC : -6.99, RSI : 33.92, STOCH (14,3) : 25.14, STOCH RSI : 0.56, UO : 27.09, Williams %R : -74.86), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Burning Rock Biotech Limited in the last 12-months were:
Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and LungPlasma. The company has developed various cancer detection products , involving tumor targeting, oncomitant diagnosis of immune drugs, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress and detection of tumor sensitivity.
CEO: Yusheng Han
Telephone: +86 2034037871
Address: No. 7, Luoxuan 4th Road, Guangzhou 510005, , CN
Number of employees: 753
